SD230821-006 page 1 of 1

PharmLabs San Diego Certificate of Analysis

3421 Hancock St, Second Floor, San Diego, CA 92110 | License: C8-0000098-LIC ISO/IEC 17025:2017 Accredited L17-427-1 #85368

sample Onyx Grandaddy Purple - Test 3

| Sample ID SD230821-006 (83057) | | Matrix Concentrate (Inhalable Cannabis Good) |
|--------------------------------|-----------------------|--|
| Tested for Wherezhemp, LLC | | |
| Sampled - | Received Aug 21, 2023 | Reported Aug 22, 2023 |
| Analyses executed CANX, QARUSH | | |

Laboratory note: The estimated concentration of the unknown peak in the sample is 1423% | Currently PharmLabs laboratory can not confirm an unidentified peak in your chromatogram due to interference (only with highly concentrated D8 products) from which we believe to be either (+)d8-THC or d9-THC. At this time there are no reference standards available for (+)d8-THC (+)d8-THC is a different compound from the main (-)d8-THC cannabinoid and, therefore, these two compounds may have different efficacies. Using the most advanced instruments and techniques available, the separation of (+)d8-THC is problematic for the scientific community as a whole. PharmLabs believes the unidentified peak to be a combination of (+)d8-THC and d9-THC with the majority. If not all, of the concentration being (+)d8-THC. Total (+/-) D8 Concentration is estimated to be: 43.4%

CANX - Cannabinoids Analysis

Analyzed Aug 22, 2023 | Instrument HPLC-VWD | Method The expanded Uncertainty of the Cannabinoid analysis is approximately **3**.806% at the 95% Confidence Level

| Analyte | LOD mg/g | LOQ mg/g | Result % | Result mg/g |
|--|-------------|-------------|-------------|----------------|
| 11-Hydroxy-Δ8-Tetrahydrocannabivarin (11-Hyd-Δ8-THCV) | 0.013 | 0.041 | ND | ND |
| Cannabidiorcin (CBDO) | 0.002 | 0.007 | ND | ND |
| Abnormal Cannabidiorcin (a-CBDO) | 0.01 | 0.031 | ND | ND |
| (+/-)-9B-hydroxy-Hexahydrocannibinol (9b-HHC) | 0.012 | 0.036 | ND | ND |
| 11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC) | 0.007 | 0.021 | ND | ND |
| Cannabidiolic Acid (CBDA) | 0.001 | 0.16 | ND | ND |
| Cannabigerol Acid (CBGA) | 0.001 | 0.16 | ND | ND |
| Cannabigerol (CBG) | 0.001 | 0.16 | ND | ND |
| Cannabidiol (CBD) | 0.001 | 0.16 | 0.94 | 9.45 |
| 1(S)-THD (s-THD) | 0.013 | 0.041 | ND | ND |
| 1(R)-THD (r-THD) | 0.025 | 0.075 | ND | ND |
| Tetrahydrocannabivarin (THCV) | 0.001 | 0.16 | 0.24 | 2.37 |
| Δ8-tetrahydrocannabivarin (Δ8-THCV) | 0.021 | 0.064 | 0.72 | 7.21 |
| Cannabidihexol (CBDH) | 0.005 | 0.16 | ND | ND |
| Tetrahydrocannabutol (Δ9-THCB) | 0.013 | 0.038 | ND | ND |
| Cannabinol (CBN) | 0.001 | 0.16 | 0.36 | 3.57 |
| Cannabidiphorol (CBDP) | 0.015 | 0.047 | ND | ND |
| exo-THC (exo-THC) | 0.005 | 0.16 | ND | ND |
| Tetrahydrocannabinol (Δ9-THC) | 0.003 | 0.16 | UI | UI |
| Δ8-tetrahydrocannabinol (Δ8-THC) | 0.004 | 0.16 | 43.48 | 434.80 |
| (6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10) | 0.015 | 0.16 | ND | ND |
| Hexahydrocannabinol (S Isomer) (9s-HHC) | 0.017 | 0.16 | ND | ND |
| (6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10) | 0.007 | 0.16 | ND | ND |
| Hexahydrocannabinol (R Isomer) (9r-HHC) | 0.016 | 0.16 | ND | ND |
| Tetrahydrocannabinolic Acid (THCA) | 0.001 | 0.16 | 33.76 | 337.65 |
| Δ9-Tetrahydrocannabihexol (Δ9-THCH) | 0.024 | 0.071 | ND | ND |
| Cannabinol Acetate (CBNO) | 0.014 | 0.043 | ND | ND |
| Δ9-Tetrahydrocannabiphorol (Δ9-THCP) | 0.017 | 0.16 | 9.43 | 94.31 |
| Δ8-Tetrahydrocannabiphorol (Δ8-THCP) | 0.041 | 0.16 | ND | ND |
| Cannabicitran (CBT) | 0.005 | 0.16 | ND | ND |
| Δ8-THC-O-acetate (Δ8-THCO) | 0.076 | 0.16 | ND | ND |
| 9(S)-HHCP (s-HHCP) | 0.031 | 0.094 | ND | ND |
| Δ9-THC-O-acetate (Δ9-THCO) | 0.066 | 0.16 | ND | ND |
| 9(R)-HHCP (r-HHCP) | 0.026 | 0.079 | ND | ND |
| 9(S)-HHC-O-acetate (s-HHCO) | 0.005 | 0.16 | ND | ND |
| 9(R)-HHC-O-acetate (r-HHCO) | 0.008 | 0.025 | ND | ND |
| 3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8) | 0.067 | 0.204 | ND | ND |
| Total THC (тнса * 0.877 + Δ 9тнс) | | | 29.61 | 296.12 |
| Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC) | | | 73.09 | 730.92 |
| Total CBD (CBDa * 0.877 + CBD) | | | 0.94 | 9.45 |
| Total CBG (CBGa * 0.877 + CBG) | | | ND | ND |
| Total HHC (9r-HHC + 9s-HHC) | | | ND | ND |

UI Unidentified ND Not Detected NA Not Applicable NT Not Reported LOD Limit of Detection LOQ Limit of Quantification <LOQ Detected NUCU. Above upper limit of linearity >ULCU. Above upper limit of linearity CFU/Q colony forming Units per 1 gram TNTC Too Numerous to Count





Authorized Signature

Brandon Starr

Brandon Starr, Lab Manager Tue, 22 Aug 2023 14:53:59 -0700



PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Accredited L17-427-1
This report shall not be reprodued except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnase, treat or prevent on disease. Results are only for samples and batches indicated. Results are reported on
Basyrol evolution unless expelition in the customer to be in compliance. The measurement of uncertainty is not included in the
Basyrol evolution unless expelition prevent.

